Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to extend its duration by one year to October 30, 2026, in response to significant dislocation in the trading price of its common stock [1][2] Summary by Sections Rights Plan Amendment - The amendment aims to increase potential dilution for any Acquiring Person if the Rights Plan is triggered, allowing stockholders to realize long-term value and reducing the likelihood of control by any person or group without proper compensation [2][4] - The Rights Plan will automatically expire on October 30, 2026, unless redeemed or exchanged earlier by the Company [4] Acquisition and Control - The Board did not adopt the extension in response to a specific takeover threat and retains the ability to engage with parties or accept acquisition proposals if deemed in the best interests of the Company and its stockholders [3] Rights Plan Details - The Rights become exercisable if an Acquiring Person acquires 10% or more of the outstanding common stock (15% for passive institutional investors) [4] - Stockholders above the threshold at the initial announcement are grandfathered but cannot increase ownership without triggering the Rights Plan [4] - Each Right allows the holder to purchase additional shares at $20.00, with a market value of twice the exercise price [4] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines, with a pipeline addressing underserved therapeutic areas [6]